CClinicalTrials.gg
RecruitingNCT06353672Updated Apr 9, 2024

A Study to Evaluate Safety and Feasibility of Robotic Liver Resection

An interventional study of Robotic liver resection in Liver Diseases and Surgery, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Zhejiang University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Registered 3 years 3 months after the study started (first participant enrolled Dec 2020, registered Mar 2024).
  • Started Dec 2020; still recruiting 5 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The robotic surgery system, the most advanced technology in minimally invasive surgery, overcame some shortcomings of laparoscopic surgery and improved the flexibility and precision of liver resection. Several studies have demonstrated that the robotic system was safe and feasible in liver surgery and might be advantageous in complex hepatic vein and hilar dissection, operative bleeding control, and biliary reconstruction. Previous comparative studies found limited evidence for significantly improved outcomes in robotic liver resection (RLR) over laparoscopic liver resection (LLR) or open liver resection (OLR), considering the various degrees of difficulty in liver surgeries.

This study aimed to evaluate safety and feasibility of robotic liver resection, by comparing it with LLR or OLR, and gain veritable and relevant data on the benefits of RLR.

02

Conditions studied

  • Liver Diseases
  • Surgery

Browse trials for

Keywords

  • Robotic liver resection
03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 50 across 1,323 interventional studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Zhejiang University is the lead sponsor of 351 studies on the registry; 165 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The patients were diagnosed with a liver tumor.
  • The patients underwent robotic liver resection.

Exclusion criteria

Exclusion Criteria:

  • The patients underwent simultaneous malignancy resection of the colorectum or other organs (except gallbladder).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Robotic liver resection

    Device: Robotic liver resection

Interventions

  • DeviceRobotic liver resection

    Liver resection using Da Vinci robotic system

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    The grades of postoperative complications were recorded following the Clavien-Dindo classification. Partial hepatic dysfunction or hepatic failure, biliary fistula, postoperative hemorrhage, pleural effusion, venous thrombosis, and surgical site infections were recorded.

    Time frame: with in 90 days after surgery

  2. Postoperative hospital stay

    The days of hospital stay after operation

    Time frame: with in 90 days after surgery

  3. Postoperative unplanned reoperation

    The unplanned reoperation due to postoperative complications

    Time frame: with in 90 days after surgery

  4. Unplanned readmission

    The unplanned readmission after discharge due to postoperative complications

    Time frame: with in 90 days after surgery

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital, Medical College of Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06353672
Lead sponsor
Zhejiang University
Responsible party
TingBo Liang (Professor, Zhejiang University) — Principal investigator
First posted
Apr 9, 2024
Start date
Dec 1, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 9, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion